MedTrace Logo

Melatonin in Smoke-induced Vascular Injury

NCT02591238 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-03-03

Study results available
· View outcomes & findings →

Summary

The main purpose of this study was to evaluate the effects of melatonin in the regulation of the vascular injury in smokers through population-based, randomized, double-blind, placebo-controlled trial.

Conditions

  • Smoking
  • Vascular System Injuries

Interventions

OTHER

non-smoker oral placebo

Participants oral placebo last 2 weeks.

DRUG

non-smoker oral melatonin

Participants oral melatonin 3 mg/day last 2 weeks.

OTHER

smoker oral placebo

Participants oral placebo last 2 weeks.

DRUG

smoker oral melatonin

Participants oral melatonin 3 mg/day last 2 weeks.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Changwei Liu, MD · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-07-31
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02591238 on ClinicalTrials.gov